Dr Bob Taylor
Contact information
Research groups
Bob Taylor
Senior Clinical Research Fellow
Vivax malaria
Dr Bob Taylor works on drug trials for vivax and falciparum malaria. In contrast with falciparum malaria, vivax malaria can relapse from dormant stage parasites in the patient’s liver. Primaquine is currently the only available drug to prevent relapse infections but can cause severe haemolysis in patients with reduced G6PD activity. Dr Taylor's research aims to determine the most effective and safest way to radically cure vivax malaria.
Podcast interview
Primaquine for vivax and falciparum malaria
Primaquine can be used both to treat vivax malaria and to prevent the transmission of falciparum malaria from human to mosquito. A shorter and age-based primaquine regimen would reduce the burden of vivax malaria. It would also allow primaquine to be used more widely to block the transmission of falciparum malaria.
Recent publications
-
Development of weight and age-based dosing of daily primaquine for radical cure of vivax malaria
Taylor WR. et al, (2021), Malaria Journal, 20
-
Arterolane-piperaquine-mefloquine versus arterolane-piperaquine and artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Kenyan children: a single-centre, open-label, randomised, non-inferiority trial.
Hamaluba M. et al, (2021), The Lancet. Infectious diseases, 21, 1395 - 1406
-
A comparative study of the proximity to nomadic travel routes and environmental factors on the occurrence of cutaneous leishmaniasis in Kohgiluyeh and Boyer-Ahmad province, south-western Iran.
Ghatee MA. et al, (2021), Transboundary and emerging diseases
-
Dynamics of G6PD activity in patients receiving weekly primaquine for therapy of Plasmodium vivax malaria.
Taylor WRJ. et al, (2021), PLoS neglected tropical diseases, 15
-
The cardiovascular effects of amodiaquine and structurally related antimalarials: An individual patient data meta-analysis
Chan XHS. et al, (2021), PLOS Medicine, 18, e1003766 - e1003766